Log in

NASDAQ:FLGT - Fulgent Genetics Stock Price, Forecast & News

-1.29 (-9.75 %)
(As of 03/30/2020 08:57 AM ET)
Today's Range
Now: $11.94
50-Day Range
MA: $14.59
52-Week Range
Now: $11.94
Volume295,888 shs
Average Volume456,752 shs
Market Capitalization$257.55 million
P/E RatioN/A
Dividend YieldN/A
Fulgent Genetics, Inc., together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. Its technology platform integrates data comparison and suppression algorithms, learning software, and genetic diagnostics tools and integrated laboratory processes. The company primarily serves hospitals and medical institutions. It markets its tests through internal sales force, as well as through independent sales representatives in the United States, Canada, the People's Republic of China, and internationally. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California.
Read More
Fulgent Genetics logo

Industry, Sector and Symbol

Industry Medical laboratories
Current SymbolNASDAQ:FLGT



Sales & Book Value

Annual Sales$32.53 million
Cash Flow$0.14 per share
Book Value$4.42 per share


Net Income$-410,000.00


Market Cap$257.55 million
Next Earnings Date5/5/2020 (Estimated)
OptionableNot Optionable

Receive FLGT News and Ratings via Email

Sign-up to receive the latest news and ratings for FLGT and its competitors with MarketBeat's FREE daily newsletter.

Fulgent Genetics (NASDAQ:FLGT) Frequently Asked Questions

How has Fulgent Genetics' stock been impacted by COVID-19 (Coronavirus)?

Fulgent Genetics' stock was trading at $10.06 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, FLGT stock has increased by 18.7% and is now trading at $11.94. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Fulgent Genetics?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fulgent Genetics in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Fulgent Genetics.

When is Fulgent Genetics' next earnings date?

Fulgent Genetics is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for Fulgent Genetics.

How were Fulgent Genetics' earnings last quarter?

Fulgent Genetics Inc (NASDAQ:FLGT) announced its quarterly earnings data on Tuesday, March, 10th. The company reported $0.04 earnings per share (EPS) for the quarter, meeting the Zacks' consensus estimate of $0.04. The firm had revenue of $8.39 million for the quarter, compared to analysts' expectations of $9.02 million. Fulgent Genetics had a negative net margin of 1.26% and a positive return on equity of 0.69%. View Fulgent Genetics' earnings history.

What price target have analysts set for FLGT?

2 equities research analysts have issued 1 year price objectives for Fulgent Genetics' shares. Their forecasts range from $12.30 to $12.30. On average, they anticipate Fulgent Genetics' stock price to reach $12.30 in the next year. This suggests a possible upside of 3.0% from the stock's current price. View analysts' price targets for Fulgent Genetics.

Has Fulgent Genetics been receiving favorable news coverage?

News articles about FLGT stock have trended somewhat negative this week, InfoTrie reports. The research firm ranks the sentiment of news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Fulgent Genetics earned a news sentiment score of -1.0 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news aboutFulgent Genetics.

Are investors shorting Fulgent Genetics?

Fulgent Genetics saw a increase in short interest in March. As of March 13th, there was short interest totaling 449,100 shares, an increase of 22.6% from the February 27th total of 366,400 shares. Based on an average trading volume of 375,800 shares, the days-to-cover ratio is presently 1.2 days. Currently, 5.1% of the company's shares are short sold. View Fulgent Genetics' Current Options Chain.

Who are some of Fulgent Genetics' key competitors?

What other stocks do shareholders of Fulgent Genetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Fulgent Genetics investors own include Crispr Therapeutics (CRSP), NVIDIA (NVDA), Alibaba Group (BABA), Baidu (BIDU), Advanced Micro Devices (AMD), Baozun (BZUN), Canopy Growth (CGC), DexCom (DXCM), TENCENT HOLDING/ADR (TCEHY) and Amarin (AMRN).

Who are Fulgent Genetics' key executives?

Fulgent Genetics' management team includes the following people:
  • Mr. Ming Hsieh, Chairman, CEO & Pres (Age 63)
  • Mr. Paul Kim, Chief Financial Officer (Age 52)
  • Dr. Han Lin Gao, Chief Scientific Officer & Lab Director (Age 52)

When did Fulgent Genetics IPO?

(FLGT) raised $60 million in an IPO on Thursday, September 29th 2016. The company issued 4,600,000 shares at a price of $12.00-$14.00 per share. Credit Suisse and Piper Jaffray acted as the underwriters for the IPO and Raymond James and BTIG were co-managers.

What is Fulgent Genetics' stock symbol?

Fulgent Genetics trades on the NASDAQ under the ticker symbol "FLGT."

Who are Fulgent Genetics' major shareholders?

Fulgent Genetics' stock is owned by many different institutional and retail investors. Top institutional investors include CA Family Wealth LLC (36.13%), Driehaus Capital Management LLC (2.94%), Old West Investment Management LLC (2.82%), Raymond James Trust N.A. (2.24%), Essex Investment Management Co. LLC (1.14%) and EAM Investors LLC (1.05%). Company insiders that own Fulgent Genetics stock include Ming Hsieh and Paul Kim. View institutional ownership trends for Fulgent Genetics.

Which institutional investors are selling Fulgent Genetics stock?

FLGT stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Raymond James Trust N.A., Mutual Advisors LLC, Old West Investment Management LLC, and Alambic Investment Management L.P.. View insider buying and selling activity for Fulgent Genetics.

Which institutional investors are buying Fulgent Genetics stock?

FLGT stock was bought by a variety of institutional investors in the last quarter, including CA Family Wealth LLC, Driehaus Capital Management LLC, Cadence Capital Management LLC, EAM Global Investors LLC, Acadian Asset Management LLC, EAM Investors LLC, Essex Investment Management Co. LLC, and Wedge Capital Management L L P NC. View insider buying and selling activity for Fulgent Genetics.

How do I buy shares of Fulgent Genetics?

Shares of FLGT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Fulgent Genetics' stock price today?

One share of FLGT stock can currently be purchased for approximately $11.94.

How big of a company is Fulgent Genetics?

Fulgent Genetics has a market capitalization of $257.55 million and generates $32.53 million in revenue each year. The company earns $-410,000.00 in net income (profit) each year or $0.02 on an earnings per share basis. Fulgent Genetics employs 123 workers across the globe. View additional information about Fulgent Genetics.

What is Fulgent Genetics' official website?

The official website for Fulgent Genetics is http://www.fulgentgenetics.com/.

How can I contact Fulgent Genetics?

Fulgent Genetics' mailing address is 4978 SANTA ANITA AVENUE SUITE 205, TEMPLE CITY CA, 91780. The company can be reached via phone at 626-350-0537 or via email at [email protected]

MarketBeat Community Rating for Fulgent Genetics (NASDAQ FLGT)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  200 (Thanks for Voting!)
Underperform Votes:  235 (Thanks for Voting!)
Total Votes:  435
MarketBeat's community ratings are surveys of what our community members think about Fulgent Genetics and other stocks. Vote "Outperform" if you believe FLGT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FLGT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/30/2020 by MarketBeat.com Staff

Featured Article: What is Call Option Volume?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel